ENPP2 and metabolic dysfunction-associated steatotic liver disease: Moreover, several clinical studies have suggested a potential role for ATX as a biomarker of nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) [18,19,20,21].